2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Study Population, Human, Adult, Animal Model
PAPER

1433 Targetable CD22 surface expression results from myeloid plasticity upon ven/AZA resistance in acute myeloid leukemia

Julia M. Unglaub, MD, Josephine Brysting2, Anne Merbach3, Binje Vick, PhD4, Zeynep Elli5, Haizhang Chen6, Christian Rohde7, Stefanie Gryzik8, Maximilian Mönnig9, Selina Neunhäuser10, Alexander Waclawiczek11, Simon Renders, MD12, Aino-Maija Leppä, MSc13, Sarah Richter, MS14, Andrei Stapran, MSc15, Tilman Schöning16, Rabia Shahswar17, Michael Heuser, MD18, Caroline Pabst, PD Dr. med.19, Simon Raffel, MD20, Michael Scherrer21, Christopher Plass22, Michael Hundemer, MD23, Tim Sauer, MD24, Judith Zaugg, Prof. Dr.25, Andreas Trumpp, PhD, Prof26, Irmela Jeremias, MD27, Carsten Müller-Tidow28, Maike Janssen29
1 University Hospital Heidelberg, Heidelberg, Germany
2 European Molecular Biology Laboratory, Molecular Medicine Partnership Unit, Heidelberg, Germany, University Hospital Heidelberg, Heidelberg, Germany
3 University Hospital Heidelberg, Heidelberg, Germany
4 German Cancer Consortium (DKTK), Partner site Munich, Munich, Germany, Helmholtz Munich, German Research Center for Environmental Health (HMGU), Munich, Germany
5 University Hospital Heidelberg, Heidelberg, Germany
6 University Hospital Heidelberg, Heidelberg, Germany
7 University Hospital Heidelberg, Heidelberg, Germany
8 Laboratory for Hematological Diagnostics,, Heidelberg, Germany, University Hospital Heidelberg, Heidelberg, Germany
9 University Hospital Heidelberg, Heidelberg, Germany
10 University Hospital Heidelberg, Heidelberg, Germany
11 Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany, Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany
12 Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany, University Hospital Heidelberg, Heidelberg, Germany
13 Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany, Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany
14 University Hospital Heidelberg, Heidelberg, Germany
15 European Molecular Biology Laboratory, Molecular Medicine Partnership Unit, Heidelberg, Germany, University Hospital Heidelberg, Heidelberg, Germany
16 Hospital Pharmacy, University Hospital Heidelberg, Heidelberg, Germany
17 Hannover Medical School, Hannover, Germany, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, Germany
18 University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany
19 University Hospital Heidelberg, Heidelberg, Germany
20 University Hospital Heidelberg, Heidelberg, Germany
21 Deutsches Krebsforschungszentrum (DKFZ), Division of Cancer Epigenomics, Heidelberg, Germany
22 Deutsches Krebsforschungszentrum (DKFZ), Division of Cancer Epigenomics, Heidelberg, Germany
23 Laboratory for Hematological Diagnostics,, Heidelberg, Germany, University Hospital Heidelberg, Heidelberg, Germany
24 University Hospital Heidelberg, Heidelberg, Germany
25 European Molecular Biology Laboratory, Molecular Systems Biology Unit, Heidelberg, Germany, University Hospital Basel, Basel, Switzerland, University Hospital Heidelberg, Heidelberg, Germany
26 Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany, Heidelberg Institute for Stem Cell Technology and Experimental Medicine, Heidelberg, Germany
27 Dr. von Hauner Children’s Hospital, LMU University Hospital, Munich, Germany, German Cancer Consortium (DKTK), Partner site Munich, Munich, Germany, Helmholtz Munich, German Research Center for Environmental Health (HMGU), Munich, Germany
28 European Molecular Biology Laboratory, Molecular Medicine Partnership Unit, Heidelberg, Germany, University Hospital Heidelberg, Heidelberg, Germany
29 University Hospital Heidelberg, Heidelberg, Germany
Acute myeloid leukemia (AML) remains a high-risk malignancy with limited therapeutic options after failure of venetoclax (VEN) plus azacitidine (AZA). AML associated cell surface molecules are often present on the surface of hematopoietic stem cells which precludes therapeutic exploitation. We discovered and investigated CD22 expression in a large AML cohort and examined its therapeutic potential using single-cell multiomics and functional studies.
 
Primary AML samples were exposed to AZA in vitro and analyzed by surface glycoproteomics, with candidate targets validated by flow cytometry. A clinical cohort of 2,691 primary AML specimens (peripheral blood and bone marrow) was analyzed; 781 with flow-cytometrically detectable blasts were evaluable, and 688 underwent AI-supported automated CD22 quantification on CD45?/SSC-defined blasts using Otsu-based thresholding with exclusion of hematogones. CD22 positivity was compared according to prior therapy exposure and disease status. CloneTracer-based single-cell RNA sequencing combined with extensive CITE-seq panels was performed on paired diagnosis and relapse samples from VEN/AZA-treated patients to define CD22 distribution across leukemic populations. Therapeutic targeting was evaluated with inotuzumab ozogamicin (InO, a CD22 antibody-drug conjugate) in CD22-positive primary AML specimens and patient-derived xenograft (PDX) models in vitro and in vivo. Clinical activity was explored in a patient with TP53-mutant AML relapsing after VEN/AZA at day +120 following allogeneic stem cell transplantation (alloSCT), who received two cycles of InO and three cycles of VEN/AZA. All patients provided written informed consent, and InO was administered off-label according to institutional practice.
 
Unbiased surface glycoproteomic profiling of AZA-treated primary AML samples unexpectedly identified CD22 as one of the most consistently induced surface antigens, a finding confirmed by flow cytometry. To determine the clinical relevance of this observation, analyses of 688 AML specimens demonstrated that CD22-positive blasts were significantly more frequent in VEN/AZA-exposed than VEN/AZA-naïve patients (p<0.01) and in relapsed/refractory disease than at first diagnosis (p<0.01), identifying CD22 as a clinically relevant feature of treatment-exposed AML. High-dimensional flow cytometry of blasts from an independent cohort of 78 patients localized CD22 expression predominantly to CD34?CD38? cells, consistent with a leukemia stem cell phenotype. CloneTracer/CITE-seq analysis of paired diagnosis and relapse samples demonstrated selective induction of surface CD22 following VEN/AZA therapy, with expression across leukemic hematopoietic stem/multipotent progenitor and early myeloid progenitor compartments. Leukemic stemness scores of CD22-expressing blast populations were comparable to, or exceeded, those of CD22-negative counterparts. In primary AML specimens and PDX models, CD22 expression correlated with increased in vitro sensitivity to InO. In an in vivo PDX model, InO reduced leukemic growth and prolonged survival. Supporting the translational relevance of these findings, a patient with TP53-mutant AML relapsing after VEN/AZA achieved a leukemia-free bone marrow following InO-based therapy and remained in ongoing remission for 15 months after a second alloSCT.
 

Using unbiased surface proteomics, we identified expression of the B-cell antigen CD22 as a consistent VEN/AZA therapy-associated feature of AML. Validation in a large clinical cohort demonstrated significant enrichment of CD22 following VEN/AZA exposure and in relapsed/refractory disease, while single-cell analyses localized this phenotype to stem-like leukemic compartments. Together with preclinical efficacy and durable clinical activity of inotuzumab ozogamicin, these findings identify CD22 as a biomarker of treatment-resistant AML and provide a rationale for biomarker-guided CD22-directed therapy trials in VEN/AZA-refractory AML.

Julia M. Unglaub, MD: No relevant conflicts of interest to declare.